Post covid 19 pulmonary fibrosis. Is it real threat?
Post covid 19 pulmonary fibrosis. Is it real threat?
复制标题
DOI：
10.1016/j.ijtb.2020.11.003
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Kumar R
中科院分区：
文献类型：
--
作者：
Rai DK;Sharma P;Kumar R
COVID-19 爆发后，全球越来越多的 COVID-19 幸存者在临床检测结果呈阴性后很长一段时间内仍在与该疾病的症状作斗争。当我们与这场大流行作斗争时，具有挑战性的部分是管理 COVID-19 后遗症，这些后遗症可能包括疲劳、身体疼痛和肺纤维化。这篇综述探讨了新冠肺炎后肺纤维化的潜在机制、危险因素、病程和治疗选择。需要 ICU 护理和机械通气的老年患者发生肺纤维化的风险最高。目前，尚无经过充分证明的治疗方案可用于治疗炎症后 COVID 19 肺纤维化。
After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.